First Mercantile Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

First Mercantile Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,031	Closed	-$117K	–	891
2021 Q1	$117K	Sell	1,031 -121	-11%	-$16.5K	0.01%	631
2020 Q4	$159K	Sell	1,152 -123	-10%	-$14.6K	0.02%	519
2020 Q3	$145K	Sell	1,275 -53	-4%	-$4.39K	0.02%	537
2020 Q2	$104K	Sell	1,328 -833	-39%	-$55.1K	0.01%	649
2020 Q1	$96K	Buy	2,161 +274	+15%	+$14.2K	0.01%	568
2019 Q4	$81K	Sell	1,887 -5	-0.3%	-$206	0.01%	728
2019 Q3	$81K	Buy	1,892 +741	+64%	+$40.3K	0.01%	750
2019 Q2	$73K	Buy	1,151 +166	+17%	+$10.6K	0.01%	707
2019 Q1	$68K	Buy	985 +495	+101%	+$28.3K	0.02%	736
2018 Q4	$21K	Sell	490 -165	-25%	-$9.02K	0.01%	854
2018 Q3	$50K	Buy	+655	New	+$53.3K	0.01%	796
2017 Q1	–	Sell	-1,954	Closed	-$137K	–	852
2016 Q4	$137K	Sell	1,954 -385	-16%	-$27.3K	0.02%	683
2016 Q3	$166K	Buy	2,339 +39	+2%	+$2.49K	0.02%	641
2016 Q2	$112K	Sell	2,300 -2,505	-52%	-$162K	0.01%	708
2016 Q1	$304K	Buy	4,805 +405	+9%	+$26.5K	0.04%	530
2015 Q4	$493K	Buy	4,400 +1,005	+30%	+$100K	0.05%	440
2015 Q3	$327K	Buy	3,395 +1,840	+118%	+$211K	0.03%	565
2015 Q2	$159K	Sell	1,555 -2,015	-56%	-$156K	0.01%	742
2015 Q1	$222K	Buy	3,570 +1,985	+125%	+$110K	0.02%	675
2014 Q4	$70K	Sell	1,585 -1,705	-52%	-$78.1K	0.01%	909
2014 Q3	$186K	Buy	+3,290	New	+$166K	0.02%	734

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

First Mercantile Trust's RARE Position: Q2 2021 in Review

First Mercantile Trust sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 1,031 shares — an estimated $117K sold.

First Mercantile Trust first reported a position in RARE in Q3 2014 and held it in 21 quarters. The position peaked at $493K in Q4 2015. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

First Mercantile Trust reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
First Mercantile Trust sold 1,031 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $117K.
First Mercantile Trust first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 21 quarters.
First Mercantile Trust's Ultragenyx Pharmaceutical position peaked at $493K in Q4 2015.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on First Mercantile Trust's 13F filing for Q2 2021, filed 10 Aug 2021.